AMERICAN JOURNAL OF HEMATOLOGY
Scope & Guideline
Championing Excellence in Hematology Research
Introduction
Aims and Scopes
- Hematological Malignancies:
The journal extensively covers research on leukemia, lymphoma, and myeloma, focusing on novel therapies, clinical trials, and molecular genetics that influence treatment and prognosis. - Transfusion Medicine:
Research related to transfusion practices, blood safety, and the management of transfusion-related complications is a key area, reflecting the journal's commitment to improving patient care in transfusion settings. - Sickle Cell Disease and Thalassemia:
Papers often explore the pathophysiology, management strategies, and innovative therapies for sickle cell disease and thalassemia, aiming to improve health outcomes for affected individuals. - Coagulation Disorders:
The journal includes research on various coagulation disorders, including hemophilia and thrombosis, focusing on new treatment modalities and strategies for management. - Stem Cell Transplantation:
There is a significant emphasis on studies related to hematopoietic stem cell transplantation, including donor selection, conditioning regimens, and post-transplant outcomes. - Clinical Trials and Therapeutics:
The journal publishes findings from clinical trials of new drugs, treatment regimens, and innovative therapies, contributing to the evidence base for clinical practice.
Trending and Emerging
- Immunotherapy and CAR-T Cell Therapy:
There is a growing emphasis on the development and application of immunotherapies, particularly CAR-T cell therapies, for hematological malignancies, showcasing innovative treatment options. - Targeted Therapy and Precision Medicine:
Research focusing on targeted therapies based on genetic and molecular profiling of hematological disorders is on the rise, reflecting a shift towards personalized treatment approaches. - Biomarkers and Minimal Residual Disease Monitoring:
Emerging studies are increasingly focusing on the identification and utilization of biomarkers for disease monitoring and prognosis, particularly in acute myeloid leukemia and other malignancies. - Health Disparities and Patient-Centered Care:
The journal is increasingly addressing health disparities within hematology, emphasizing the importance of equitable care and patient-reported outcomes in treatment strategies. - Long-term Effects of COVID-19 on Hematology Patients:
Research exploring the implications of COVID-19 on patients with existing hematological conditions, including vaccine responses and management challenges, has gained prominence. - Artificial Intelligence and Machine Learning in Hematology:
There is a notable trend towards integrating artificial intelligence and machine learning into hematology research, particularly in diagnostics and treatment personalization.
Declining or Waning
- Traditional Chemotherapy Approaches:
There is a noticeable decrease in studies focusing solely on traditional chemotherapy regimens as the field moves towards targeted therapies and immunotherapies, which are now the focus of many clinical trials. - Basic Science Research:
The journal has shifted towards more clinically relevant studies, with a waning interest in purely basic science research that does not directly translate to clinical applications. - Epidemiological Studies:
Although still important, there appears to be a reduction in the volume of studies that solely focus on the epidemiology of hematological disorders, as the emphasis shifts towards treatment outcomes and therapeutic innovations. - Longitudinal Studies in Hematology:
Fewer longitudinal studies are being published, as funding and interest may be shifting towards more immediate, impactful clinical trials and translational research.
Similar Journals
Journal of Hematology
Exploring the Depths of Hematological ResearchThe Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Advancing pediatric care through groundbreaking research.JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, published by Lippincott Williams & Wilkins, serves as a vital platform for the dissemination of cutting-edge research and insights in the fields of pediatric hematology and oncology. Since its inception in 1979, the journal has maintained a commitment to advancing knowledge through peer-reviewed articles that contribute to the understanding and treatment of blood disorders and cancers in children. With an impact factor reflective of its academic contributions, the journal is positioned in the Q3 quartile across key medical categories — Hematology, Oncology, and Pediatrics, Perinatology and Child Health — indicating its relevance and influence in the field. While it does not currently offer open access options, the journal remains a crucial resource for researchers, clinicians, and students dedicated to improving pediatric care and outcomes. Researchers are encouraged to contribute to this esteemed journal as it seeks to bridge the gap between clinical practice and research, fostering innovation and improved quality of life for young patients affected by hematologic and oncologic conditions.
Transfusionsmedizin
Elevating transfusion practices through peer-reviewed excellence.Transfusionsmedizin is a premier journal dedicated to the field of transfusion medicine, published by the renowned GEORG THIEME VERLAG KG. With an ISSN of 2191-8805 and an E-ISSN of 2191-8813, this journal serves as a vital platform for disseminating cutting-edge research and clinical advancements in blood transfusion practices. Although it operates under a subscription model, the journal is committed to high-quality peer-reviewed content that addresses contemporary challenges and innovations in transfusion therapy. By fostering dialogue among researchers, clinicians, and students, Transfusionsmedizin aims to advance patient care and enhance the safety and efficacy of transfusion practices globally. Its contributions are essential for professionals engaged in transfusion science, hematology, and related medical fields, solidifying its reputation as a critical resource for staying abreast of the latest developments in transfusion research.
Journal of Blood Medicine
Elevating Standards: The Premier Source for Blood Medicine InsightsThe Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.
Hematology-American Society of Hematology Education Program
Fostering Excellence in Hematological ResearchHematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.
BLOOD COAGULATION & FIBRINOLYSIS
Bridging Molecular Insights and Clinical ApplicationsBLOOD COAGULATION & FIBRINOLYSIS, a distinguished journal in the field of hematology, is published by Lippincott Williams & Wilkins, a reputable name in academic publishing. Since its inception in 1990, this journal has been committed to advancing the understanding of blood coagulation and fibrinolysis, focusing on the molecular mechanisms, clinical implications, and therapeutic aspects of these critical processes. With an impact factor reflecting its significance within the academic community, currently ranking Q3 in both Hematology and Miscellaneous Medicine for 2023, this journal serves as a pivotal platform for researchers and professionals alike. By providing access to cutting-edge research and reviews, BLOOD COAGULATION & FIBRINOLYSIS endeavors to foster collaboration and innovation in the treatment of coagulation disorders. Interested readers can explore ongoing contributions to the field through subscriptions and institutional access options.
Hematology Transfusion and Cell Therapy
Pioneering insights in hematology and transfusion care.Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.
Indian Journal of Hematology and Blood Transfusion
Exploring Innovations in Blood Disorders and Transfusion ScienceIndian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.
TRANSFUSION AND APHERESIS SCIENCE
Empowering Research for Enhanced Patient Outcomes in HematologyTRANSFUSION AND APHERESIS SCIENCE, published by Pergamon-Elsevier Science Ltd, serves as a pivotal platform for researchers and practitioners in the fields of hematology, transfusion medicine, and apheresis. With an ISSN of 1473-0502 and an E-ISSN of 1878-1683, this peer-reviewed journal boasts a respectable Q3 ranking in the Hematology category as of 2023, positioning it within the 45th percentile among its counterparts. Operating from the United Kingdom, it provides comprehensive insights into the latest advancements and methodologies in transfusion practices and apheresis technology, crucial for enhancing patient care and therapeutic strategies. The journal's scope, covering key developments from 1996 to 2024, allows for a deep exploration of historical and emerging trends within the discipline. Moreover, its open access options facilitate widespread dissemination of research findings, fostering collaboration and innovation in the scientific community. For those dedicated to advancing knowledge in hematology, TRANSFUSION AND APHERESIS SCIENCE represents an essential resource, bridging theory and practice in this vital area of healthcare.
Blood Research
Transforming Knowledge into Clinical ExcellenceBlood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.